Anke Biotechnology: Joint venture company PA3-17 injectable approved for entry into key phase II clinical trials.

On the evening of September 17th, Anke Biotechnology announced that its affiliated company, Bo Shengji Medical Technology Co., Ltd., and Bo Shengji Anke Cell Technology Co., Ltd., had received the meeting minutes of the PA3-17 Injection Phase II communication meeting issued by the National Medical Products Administration's Drug Evaluation Center, agreeing for the applicant to conduct the critical Phase II clinical trial of PA3-17 Injection. It is reported that PA3-17 Injection is the world's first autologous CAR-T cell therapy product targeting CD7 developed independently by Bo Shengji Anke, approved for new drug clinical trials, used to treat adult relapsed, refractory CD7-positive hematologic malignancies.